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ABSTRACT: Vitamin K antagonists (VKA) have long been the default drugs for anticoagulant management in venous throm-
bosis. While eﬃcacious, they are diﬃcult to use due to interpatient dose−response variability and the risks of bleeding. The approval
of fondaparinux, a heparin-derived factor Xa (fXa) inhibitor, provided validation for the development of direct oral anticoagulants
(DOAC), and currently such inhibitors of thrombin and fXa are in clinical use. These agents can be used without regular
coagulation monitoring, but the inherent risk of bleeding complications associated with blocking the common coagulation
pathway remains. Eﬀorts are now underway to develop DOACs that inhibit components of the intrinsic and extrinsic coagulation
cascades upstream of thrombin and fX. Evidence from humans and from transgenic animal models suggests that this strategy may
provide a better therapeutic margin between antithrombotic and antihemostatic eﬀects. Here the design of active-site inhibitors
of S1A proteases involved in coagulation and ﬁbrinolysis is summarized.
■ INTRODUCTION
Hemostasis, Thrombosis, and Fibrinolysis. Mammalian
hemostasis, i.e., the formation of blood clots consisting of
aggregated platelets and polymerized ﬁbrin, is a physiological
process that prevents bleeding upon injury to blood vessels.
Thrombosis, on the other hand, is generally regarded as a
pathological form of hemostasis, e.g., in arterial thrombosis
as a result of atherosclerosis and in venous thrombosis due to
interrupted blood ﬂow, blood vessel irritation, and hyper-
coagulability.1 However, thrombosis also plays an important
role in the ﬁght against pathogens, and such immunothrom-
bosis, unless uncontrolled, is beneﬁcial to the human host.2
Formation of blood clots following vascular injury allows time
for endothelial repair of the aﬀected blood vessels. Once the
vessel endothelium has been repaired, ﬁbrinolysis sets in to
remove the ﬁbrin clot and to reinstate normal blood ﬂow.
Fibrinolysis is altered in some congenital disorders and especially
during pathological overactivation (hyperﬁbrinolysis) upon severe
injury or surgery.3
Initiation of Coagulation through the Extrinsic Path-
way. Hemostasis is a complex process composed of two main
components: platelet aggregation and platelet plug forma-
tion (primary hemostasis) and deposition of ﬁbrin through
the coagulation cascade (secondary hemostasis), although the
interplay and spatiotemporal control of these components
under pathophysiological conditions in vivo remain incom-
pletely understood.4 One hypothesis1 holds that when a vascular
injury occurs, the local blood vessel endothelium is disturbed,
leading to exposure of the blood to collagen, which, together
with other factors, causes activation of circulating platelets.
At the injury site these activated platelets adhere to exposed
collagen below the endothelium through their van Willebrand
factor (vWf) receptors and form an initial mechanical plug.5
At the same time tissue factor (TF), which is expressed on
subendothelial cells, is exposed to blood and interacts with
circulating fVIIa and the resulting TF−fVIIa complex activates
the coagulation cascade (Figure 1) through the extrinsic path-
way. As a result, sequential activation of fX and prothrombin
results in formation of thrombin, which in turn converts ﬁbri-
nogen to polymerized ﬁbrin. Additionally, thrombin activates
several other coagulation factors, thus amplifying the coagula-
tion cascade. Thrombin also further activates platelets, whose
adherence to each other is promoted by the binding of platelet
glycoprotein (Gp) IIb/IIIa to ﬁbrinogen.6 The combined
actions of the platelet plug and the ﬁbrin mesh then provide a
mechanically stable thrombus, which is further sealed through
ﬁbrin polymer cross-linking by fXIIIa, the only coagulation
factor that is not a protease but a transglutaminase.7
Initiation of Coagulation through the Intrinsic Path-
way. Whereas activation of blood coagulation through the
extrinsic pathway is understood well, the exact physiological
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relevance of the contact activation (intrinsic) pathway remains
less clear. Originally it was thought that contact activation was
necessary for initiation of coagulation, although the physio-
logical activating surfaces had not been identiﬁed.10,11 It has
been known for a long time that in a test tube blood coagulates
rapidly due to contact with glass and that many other anionic
hydrophilic surfaces can initiate coagulation. The activated
partial thromboplastin time (aPTT) assay, used as part of a
series of medical blood coagulation screening tests, is based on
this principle, where materials such as kaolin, micronized silica,
or ellagic acid provide a surface for activation.12 Following the
proposal that coagulation in general is initiated through the
intrinsic pathway, it later transpired that this was unlikely to be
the case, since people deﬁcient in fXII, prekallikrein, and HK,
i.e., the components known to be involved in contact activation,
were observed not to exhibit hemostatic defects, in stark con-
trast to people with deﬁciencies in factors of the extrinsic and
common pathways, who do display such defects.13 These obser-
vations led to the current belief that physiological hemostasis is
initiated exclusively through the extrinsic pathway, although
contact activation leading to coagulation and thrombosis plays a
role in pathological states such as sepsis and acute respiratory
distress syndrome and sometimes as a consequence of blood
exposure to artiﬁcial surfaces of medical devices.14
The question of the role of contact activation in vivo has
still not been fully answered, however. While a number of
intrinsic materials capable of accelerating activation of fXII to
fXIIa, including polyphosphates, heparins, misfolded protein
aggregates, and oligonucleotides, have been identiﬁed,15
such activation may not involve classical contact activation.16
Currently it is believed that the likely physiological roles of
fXIIa include a support role in the maintenance of thrombus
stability via polyphosphates from activated platelets, as well as
local regulation of vascular permeability through activation
of the kallikrein−kinin system (KKS) and formation of the
proinﬂammatory peptide bradykinin.17 What has recently become
clear from animal studies, however, is an important and direct
involvement of fXIIa-mediated coagulation in thrombosis rather
than in hemostasis.15 These recent ﬁndings are potentially of
great importance in the development of new antithrombotics
targeting intrinsic coagulation factors, which may provide
anticoagulant activity devoid of bleeding side eﬀects.14
Anticoagulation and Fibrinolysis. Because the main-
tenance of vascular homeostasis is of paramount importance in
life, coagulation needs to be tightly controlled. This is probably
the reason for the existence of a multilayered coagulation
cascade, which allows ﬁne control through crosstalk at multiple
levels.18 Under normal conditions anticoagulant signaling
prevails over procoagulant activities. Anticoagulation pathways
converge predominantly on protein C, which is activated to
aPC on the endothelium by the thrombin−thrombomodulin−
endothelial protein C receptor (EPCR) complex. Once formed,
aPC counteracts coagulation in concert with its cofactor protein
S by cleaving and inactivating fV and fVIII, i.e., the cofactor
Figure 1. Roles of S1A proteases in coagulation and ﬁbrinolysis (adapted from ref 8, https://www.frontiersin.org/articles/10.3389/fcimb.2014.
00128/full). The extrinsic pathway of coagulation (TF pathway) mediates clot formation following vascular injury via fVII, whereas the intrinsic
pathway (contact activation system) is initiated predominantly upon inﬂammation and activation of the innate immune system during infection by
fXII in complex with prekallikrein and high-molecular weight kininogen (HK). The intrinsic and extrinsic pathways converge in the common
coagulation pathway, which culminates in the formation of ﬁbrin clots. Anticoagulation is mediated at the level of fV and fVIII by protein C (with the
cofactors protein S and protein Z, which are not enzymatically active but are related to other coagulation factors). Fibrin clots are degraded through
ﬁbrinolysis, predominantly by activated plasmin. The inset is a cladogram showing the phylogenetic relationship between coagulation proteases
based on multiple sequence alignment (Clustal Omega and ClustalW Phylogeny).9
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precursors required for activation of prothrombin and fX,
respectively.19 Additional important physiological anticoagula-
tion mechanisms include tissue factor pathway inhibitor, a
Kunitz-type Ser protease inhibitor that operates at the level of
fVIIa and fXa, and the serpin antithrombin that targets not only
thrombin but several of the other coagulation Ser proteases.
Both are endothelial surface proteins whose anticoagulant
activity is enhanced by heparin.20,21
The other mechanisms that counteract coagulation when a
thrombus has already been formed involve platelet disaggrega-
tion and ﬁbrinolysis. The latter process is mediated by plasmin,
which is formed from its precursor plasminogen by the action
of tissue and urokinase-like plasminogen activators (tPA, uPA).
Whereas tPA is released by endothelial cells, uPA is released
predominantly by monocytes and macrophages. Plasmin may
also have direct roles in anticoagulation at the level of fVa and
fVIIIa and in platelet disaggregation at the level of vWf.22
Structure and Functions of S1A Proteases. The pro-
teases responsible for the regulation of coagulation (Figure 1),
as well as some proteases involved in digestion and comple-
ment activation, belong to the S1A family of the PA(S) clan of
peptidases (MEROPS classiﬁcation23), with chymotrypsin A as
the prototype example. The S1A proteases contain His,
Asp, and Ser as the catalytic triad24 in a catalytic domain of
∼220 amino acid residues, and this unit is extended N-terminally
in many cases but rarely C-terminally (refer Figure 2 for
sequence alignment). These proteases are expressed as single
polypeptide chain zymogens that generally lack enzymatic
activity, and they are activated through regulated proteolysis by
other proteases or through autoproteolysis (Figure 3). In most
cases activation entails proteolytic cleavage, which results in
disulﬁde-bond-tethered two-chain protease forms consisting of
a light chain that contains the protease catalytic domain and a
heavy chain with several domains responsible for interactions
with partner proteins.25
■ BLOOD COAGULATION AND FIBRINOLYSIS S1A
PROTEASES AS PHARMACOLOGICAL TARGETS
Introduction. Whereas several of the factors in the coagula-
tion cascade are being pursued as pharmacological targets for
the development of new antithrombotic agents, the anticoagu-
lant protein C is currently being investigated as a new inhibitor
target for the treatment of hemophilias,26 and certain proteases
implicated in ﬁbrinolysis provide a drug discovery rationale
for the treatment of postoperative bleeding. The following
discussion will be conﬁned to proteases that are relevant to car-
diovascular diseases, even though some S1A proteases involved
in hemodynamic homeostasis, e.g., uPA and tPA, for which
selective inhibitors are also being developed,27,28 provide phar-
macological rationales for other indications, such as tumor
metastasis in the cases of uPA and tPA.29
Thromboprophylaxis and Anticoagulants: Eﬃcacy
and Bleeding Side Eﬀects. Anticoagulant drugs are used
for prophylaxis and treatment of thromboembolic disorders,
such as deep-vein thrombosis, pulmonary and systemic embo-
lisms, as well as coronary and cerebral ischemias. All of these
disorders are characterized by the formation of blood clots in
the vasculature. Anticoagulants such as heparin or warfarin, and
more recently direct thrombin and fXa inhibitors, which target
ﬁbrin formation, are mostly used for conditions involving
venous clots in deep-vein thrombosis and pulmonary embolism
and especially in people with atrial ﬁbrillation (AF) or transient
ischemic attacks to prevent ischemic strokes. Antiplatelet agents
such as aspirin, ADP receptor inhibitors, and GpIIb/IIIa
inhibitors, on the other hand, are more eﬀective for preventing
arterial clots and are used to prevent thrombotic cerebrovas-
cular and cardiovascular disease.36
According to the statistics of the World Health Organization
(WHO), ischemic heart disease and cerebrovascular disease,
which in 2008 together accounted for a societal burden of over
100 million disability-adjusted life years (DALYs)37 globally,
are both expected to be among the four leading causes of
DALYs by 2030 (together ∼10% of all DALYs).38 The latest
global data from 2013 show that nearly a third of all deaths as a
result of cardiovascular disease, especially ischemic heart disease
and ischemic stroke and the increase in the total number of
cardiovascular deaths, are believed to be due in large part to the
aging and growth of populations.39
Until recently, the mainstays of thromboprophylaxis and
anticoagulant therapy were VKAs, especially warfarin, and
Figure 2. Multiple sequence alignment (Clustal Omega) of the protease domains of the following human S1A proteases: chymotrypsin B1 (CtB1),
thrombin (thro), fVII, fIX, fX, fXI, fXII, urokinase-like plasminogen activator (uPA), tissue plasminogen activator, (tPA), protein C (proC), kallikrein
B1 (KlB1), and plasmin (Plmn). The residue numbering is that for CtB1. Subsites of the substrate recognition sites are colored as follows: S4, red;
S3, dark green; S2, blue; S1, yellow; S1′, pink; S2′, cyan; S3′, brown; S4′, light green. The catalytic residues (H57, D102, S195) are indicated in bold.
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low-molecular weight heparins (LMWHs). Both LMWHs and
VKAs inhibit blood coagulation indirectly. LMWHs enhance
the interaction of fXa and to a lesser extent thrombin, with the
natural inhibitor antithrombin,40 whereas VKAs interfere with
the γ-carboxylation of glutamate residues in vitamin K-dependent
proteins, including thrombin, fVII, fIX, and fX, which require
Figure 3. Substrate (and inhibitor) binding sites of proteases can be divided into subsites based on how they recognize their macromolecular
substrates. The substrate residues upstream (toward the N-terminus) and downstream (toward the C-terminus) of the scissile bond are designated
P1, P2, etc. and P1′, P2′, etc., respectively.30 In the protein surface representations of fXa (a; PDB code 1C5M31) and thrombin (b; PDB code
1SGI32) the subsites (S1, S2, etc.) that recognize the corresponding peptide substrate (P) residues are indicated.33 The catalytic triad of residues in
the enzymes that mediate P1−P1′ peptide bond hydrolysis are H57, D102, and S195 (chymotrypsin numbering system; residue side chains shown as
gray CPK-colored sticks). Following conversion of the zymogen forms of proteases to the apo-forms, two dominant forms of the enzymes exist in
equilibrium: an inactive form (shown for thrombin in part c; PDB code 3BEI34) with the side chain of W215 and the entire segment 215−219 (stick
models) collapsed in the active site, and the active form (d; PDB code 1SGI32), where the indole of W215 moves, together with the entire 215−219
segment, to open the active site and to form the S1 pocket.35 This illustration and illustrations of protein 3D structures in all subsequent ﬁgures were
created using the PyMOL Molecular Graphics System, version 1.7.6.0, Schrödinger, LLC, New York.
Figure 4. (a) Classical VKAs have a narrow therapeutic margin: adjusted odds ratios of ischemic stroke and intracranial bleeding as functions of
anticoagulation intensity (expressed as prothrombin time international normalized ratio, INR) with warfarin are shown (adapted with permission from
ref 43, Copyright 2006 Elsevier (http://www.sciencedirect.com/science/journal/00493848/117/5?sdc=2)). Current guidelines recommend an INR
target range of 2−3 during monitoring,43 and it can be seen that INR < 2 will not provide protection from ischemic stroke, whereas INR > 3 represents a
signiﬁcant risk of intracranial bleeding. (b) A way of determining the therapeutic margin of anticoagulants based on the steepness of their dose−response
curves in terms of clotting activity in plasma was proposed recently.44 The steepness of a dose−response curve can be evaluated using the Hill coeﬃcient
from the Hill equation: θ = 1/((Kd/[L])
n + 1), where θ is the fractional receptor occupancy (coagulation activity), Kd is the dissociation constant of the
anticoagulant, L is the ligand (anticoagulant), and n is the Hill coeﬃcient. For hypothetical anticoagulants with identical Kd (10
−7 M) and n = 1, 2, or 3, it
can be seen (adapted from ref 44, https://www.nature.com/articles/srep29387) that variation in coagulation activity of, say, 50 ± 20% (gray box) will
result from dose variations as a percentage of Kd of 190% for n = 1 (green box), 87% for n = 2 (blue box), and 57% for n = 3 (red box).
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.7b00772
J. Med. Chem. XXXX, XXX, XXX−XXX
D
γ-carboxylation for their procoagulant activity.41 Because of the
considerable diﬃculties associated with the clinical use and
management of these drugs (Figure 4), extensive eﬀorts have
been underway over the past few decades in the pharmaceutical
sector to ﬁnd better anticoagulant drugs that can be given
orally, have predictable dose−response and pharmacodynamics,
have rapid onset and oﬀset of action, display a wide therapeutic
window, and are devoid of food−drug and drug−drug inter-
actions. Such agents would hopefully obviate the cost and
inconvenience of regular coagulation monitoring and dose
adjustment, which are required for the safe and eﬀective clinical
use of VKAs and LMWHs.42
The ﬁrst new generation anticoagulants (new oral antico-
agulants, NOACs; now direct oral anticoagulants, DOACs),
including the thrombin inhibitors argatroban (2; Figure 6)45
and dabigatran etexilate (4a),46 and the fXa inhibitors
rivaroxaban (22; Figure 9),47 apixaban (23),48 and edoxaban
(24),49 are now approved for thromboprophylaxis and are
being prescribed at ﬁxed doses without the need for
anticoagulant monitoring.50 The main reason why these new
agents are now often preferred is not because they necessarily
have a wider therapeutic margin than VKAs and heparins
(Figure 4) but because they generally have more predictable
disposition properties. Since bleeding side eﬀects are still
limiting the use of DOACs,51−53 highly selective agents are now
sought that speciﬁcally target components of the coagulation
system that are involved in thrombosis but that are not impli-
cated in the induction of systemic hypocoagulation, thus avoiding
bleeding complications.14,54,55
■ DRUG DISCOVERY OVERVIEW
Factor II (Thrombin). Functions and Biomedical Rationale.
Prothrombinase, i.e., the fXa−fV complex, converts prothrom-
bin to thrombin, which in turn cleaves ﬁbrinogen to ﬁbrin
(Figure 1). Fibrinogen consists of two identical subunits, each
containing three nonidentical polypeptide chains, whose
N-termini constitute the so-called E region. Two of the chains
start with 16-residue ﬁbrinopeptide sequences that are removed
through thrombin proteolytic activity. Once the ﬁbrinopeptide
portions have been cleaved, monomeric ﬁbrin polymerizes spon-
taneously to insoluble ﬁbrin. Thrombin recognizes the ﬁbrinogen
E region through exosite I (Figure 5a,b), which positions the
ﬁbrinopeptide portions of ﬁbrinogen for productive proteolysis
by thrombin.56
Complete deﬁciency of prothrombin is believed to be incom-
patible with life, and in mice it results in embryonic and
neonatal lethality.57 When prothrombin-null mice were
reconstituted with human prothrombin to 5−10% of wild-
type levels by transgene expression, this phenotype was
observed to be reversed and animals developed normally and
did not bleed spontaneously unless traumatized.58 Because of
the very low incidence of congenital prothrombin deﬁciencies
in humans, a genotype−phenotype correlation has been diﬃ-
cult to ascertain, but defects in the prothrombin gene can lead
to moderate or severe bleeding symptoms, including mucosal
and surgical- or trauma-associated bleeding, joint bleeding, and
intracranial hemorrhages, depending on prothrombin levels.59
Inhibitor Design. Of all the S1A proteases, thrombin has
been studied most intensively in terms of active-site inhibitor
design. Already in the 1970s peptide aldehyde and other
covalent and noncovalent inhibitors modeled on known scissile
thrombin substrates were reported (reviewed in ref 64). Such
compounds, e.g., 1 (H-D-Phe-Pro-Arg-CH2Cl, PPACK;
65
Figure 6a), permitted for the ﬁrst time elucidation of the
three-dimensional structure of thrombin by X-ray crystallog-
raphy based on stable active site-inhibited enzyme forms,66,67
thus opening the door to structure-based drug design.
Early covalent tripeptide arginal and arginyl chloromethyl
ketone inhibitors were found to be too toxic for clinical use, and
one of the earliest noncovalent reversible thrombin active site
inhibitors is argatroban (2), a compound whose discovery was
reported in 1984 and that possesses good potency against
thrombin (Ki ≈ 20 nM) and selectivity with respect to
trypsin, fXa, plasmin, and PK (>100-fold).68 Argatroban (2)
obtained its ﬁrst approval in 2000 and remains in clinical use
for anticoagulation in patients with heparin-induced thrombo-
cytopoenia type II who require parenteral antithrombotic
treatment.45
Figure 5. Thrombin contains three distinct interactions sites for its binding partners. (a) Superposition of the X-ray crystal structures of the
complexes between thrombin (electrostatic surface coloring) and an octasaccharide fragment of heparin (gray CPK stick model; PDB code
1XMN),60 the fragment Eht of the central region of ﬁbrinogen (yellow cartoon; PDB code 2A45),
61 the TME456 fragment of thrombomodulin
(magenta cartoon; PDB code 1DX5),62 and an anti-thrombin IgA paraprotein (cyan cartoon; PDB code 5E8E).63 The thrombin structure shown is
that from the 1XMN complex, including the active-site-bound 1 (green stick model; refer to Figure 6a). (b) View of the cationic thrombin exosite I,
including the CDRH3 loop of the antithrombin IgA paraprotein that makes direct contact with this exosite (cyan cartoon). (c) View of the cationic
thrombin exosite II with the bound heparin octasaccharide.
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Thrombin is unusual among the S1A proteases in that it
possesses a nine-residue insertion at position 60 (Figure 2).
Two of the residues from this insertion, Y60a and W60d, can
be seen to make van der Waals interactions with the ligand
pyrrolidine ring in the thrombin complex with 1 (Figure 6b).
Most S1A proteases can accommodate substrate and inhibitor
peptides with comparatively large and varying P2 residues,
whereas thrombin prefers Gly or Pro due to a constrained
S2 site (Figure 3b). This diﬀerence is also relevant to small-
molecule inhibitor selectivity design. Practically all known
thrombin inhibitors do not occupy the S1′−S4′ sites because
of this restricted S2 site, which forms a bottleneck between
the S1−S4 and the S1′−S4′ subsite portions of the substrate
recognition cleft. The peptidomimetic 3, an extended derivative
of 4b in which the terminal thiazole group occupies part of
the S1′ site (Figure 6c), is one of the few exceptions.
From the outset in the 1980s, the design of active-site
thrombin inhibitors aimed at oral agents, since warfarin and
coumarin anticoagulants then used were also usually adminis-
tered orally.69 Early inhibitors were modeled on Phe-Pro-Arg
tripeptides, and it was thought that a basic guanidine or
benzamidine group was a prerequisite for high potency, due to
a strong salt bridge interaction between such groups and the
carboxyl function in the side chain of D189 at the base of the
S1 pocket (Figure 6b,d) contributing signiﬁcantly to binding.
However, compounds with highly basic groups are fully ionized
under physiological conditions of pH and therefore generally
possess poor membrane permeability and hence display low
gastrointestinal absorption. This is the case with, for example,
melagatran (5b), which has three ionizable groups (carboxylic
acid, pKa = 2.0; 2° amine, pKa = 7.0; benzamidine, pKa = 11.5)
and thus exists predominantly as the dibasic macroscopic
species at the site of intestinal absorption (pH ≈ 6). As a
consequence, 5b displayed very low in vitro gastrointestinal
permeability (Papp = 0.03 × 10
−6 cm·s−1 in a CaCo-2 in vitro
permeability assay)70 and low oral bioavailability in humans
(3−7%).71 The solution to this problem was a double prodrug,
ximelagatran (5a), in which the benzamidine group was
converted to the much less basic benzamidoxime function
(pKa = 5.2) and the carboxylic acid was converted to the ethyl
ester. Interestingly, the 2° amine in 5a was also found to be
signiﬁcantly less basic (pKa = 4.5) than the corresponding
amine in 5b.71 As a result, 5a exists mainly as the neutral
macroscopic species in vivo, which has better (albeit still
limited) membrane permeability (Papp = 2.4 × 10
−6 cm·s−1)
and oral bioavailability in humans (18−24%). The prodrug 5a
itself has negligible thrombin-inhibitory activity but is rapidly
converted to bioactive 5b following absorption. Clinical trials
with 5a showed much improved predictability of disposition
and a wider therapeutic window than warfarin. On this basis 5a
obtained early regulatory approvals as an anticoagulant in some
territories and indications as the ﬁrst non-VKA oral anti-
coagulant, although it was discontinued in 2004 due to liver
toxicity concerns.54
Figure 6. (a) Chemical structures of thrombin inhibitors; examples of inhibitors with more or less basic substituents (blue) that occupy the S1 site of
the enzyme are shown: 2, argatroban;67 3, RWJ-50215;72 4a, dabigatran etexilate prodrug and 4b, dabigatran;73 5a, ximelagatran prodrug and 5b,
melagatran;74 6, BM14.1248;75 7, compound 14 from ref 76; 8, RWJ-671818;77 9, compound 34 from ref 78; 10a, AZD8165 prodrug and its active
parent compound 10b;79 11, compound 1u from ref 80. (b) The binding mode of 1 (green CPK stick model) in thrombin (PDB code 1PPB66)
shows a covalent bond between one of the imidazole N atoms of H57 and the α-C of the methyl ketone as a result of nucleophilic attack and
substitution of the Cl in the ligand, as well as a hemiketal bond between the S195 side chain O and the ligand methyl ketone carbonyl C. The Arg
side chain of the ligand is buried in the deep S1 pocket (gray CPK surface) and makes polar interactions (yellow broken lines) with D189 at the base
of the pocket. (c) Superposition of thrombin-bound conformations of 1 (green, PDB code 1PPB66), 3 (magenta, PDB code 1A4W72), and 9 (cyan,
PDB code 1SL378); the protein surface (gray CPK) of the complex with 9 is shown. Close-up views of the interactions of 1 (d; polar interactions in
yellow) and 9 (e; Cl−π interaction in black) in the S1 site.
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Dabigatran (4b) is structurally related to 5b but contains a
benzimidazole unit in place of the proline-derived cores of
earlier compounds. It was designed using the crystal structure
complex of 39 (Figure 11) with thrombin as a starting
point.67,73 It potently inhibits thrombin (Ki = 4.5 nM) and has
much lower activity against other S1A proteases but also
inhibits trypsin (Ki = 50 nM).
73 As is observed with most
thrombin inhibitors (Figure 6c), its aﬃnity derives from polar
interactions with the S1 site and (mostly lipophilic) interactions
in the S2−S4 sites. Because of its high polarity (log D7.4 =
−2.4) and extent of ionization at physiological pH values, 4b is
not orally bioavailable.81 A double prodrug, dabigatran etexilate
(4a), in which the benzamidine was masked as a carbamate
ester, was subsequently developed. This agent obtained its ﬁrst
approval in 2009 and is now used globally in deep venous
thrombosis and pulmonary embolism, as well as for stroke pre-
vention in AF.81 This compound is still weakly basic (carbamic
acid hexyl ester, pKa = 6.7; benzimidazole, pKa = 4.0) and has
comparatively low oral bioavailability in humans (mean of
6.7%) and therefore has to be given at comparatively high
doses.46 However, low oral bioavailability appears to be mostly
a result of P-gp-mediated eﬄux from epithelial cells upon
absorption rather than low intrinsic permeability (a bidirec-
tional CaCo-2 assay eﬄux ratio of 13.8 was reported and a
Papp,A−B value of 29 × 10
−6 cm·s−1 in the presence of complete
P-gp blockage).82 This has been conﬁrmed in clinical trials, where
it was found that exposure to 4b following coadministration of 4a
and the P-gp inhibitor verapamil was increased signiﬁcantly.83
From the foregoing it is clear that the currently approved
thrombin inhibitors 4a and 5a are not completely satisfactory
from a pharmaceutical viewpoint, despite the fact that they
represent a signiﬁcant advance on earlier anticoagulants in
terms of safety and eﬃcacy. Much eﬀort has been expended in
the discovery of less basic and less polar thrombin inhibitors
that would be orally bioavailable without the need for prodrug
strategies. These studies showed that small ligand-eﬃcient
and potent inhibitors of much lower basicity than the early
guanidine- and amidine-containing compounds could indeed be
found and that these could still form productive polar
interactions with D189 in the S1 pocket. Examples are the
pyridine 6 (Ki = 23 nM)
75 and the benzylamine 7 (Ki = 2.1 nM
and orally bioactive),76 and especially the oxyguanidine 8
(Ki = 1.3 nM and 100% orally bioavailable in dogs).
77
Compounds with nonionizable groups that interact with the
S1 site have also been reported, and an early example is the
dichlorophenyl derivative 11 (Ki = 3 nM),
80 as well as the
extraordinarily potent chlorophenyltetrazole 9 (Ki = 1.4 pM).
78
These compounds still interact with the S1 pocket, but the
polar interactions of basic groups with D189 are replaced by
electrostatic interactions in which the ligand Cl group interacts
in an edge-to-face manner with the aromatic π system of Y228
(Figure 6d,e). Such halogen−π interactions are still poorly
understood84 and appear to arise from long-range electrostatic
and dispersion interactions, but it is clear that they can con-
tribute signiﬁcantly to binding aﬃnity (in the order of ΔΔG
values of −10 kJ·mol−1).85 A number of thrombin inhibitors that
do not contain highly basic S1-interacting groups have been
evaluated in clinical trials, but none appear to have progressed
to date. The latest addition to the list of these agents is 10a,
an ester prodrug of the carbinol 10b, which retains the
P1-interacting group of 9 (Ki = 0.3 nM).
79 Despite its favorable
pharmaceutical properties and performance in preclinical
studies, this compound does not appear to have progressed.
Indirect Inhibitors. Fibrinogen is not the only substrate that
is processed by thrombin, which also cleaves and activates fV,
fVIII, fXI, and fXIII. Recognition of these substrates invariably
involves one or both of the thrombin exosites (Figure 5), as
well as the active site cleft.86 Thrombomodulin, which switches
thrombin speciﬁcity from procoagulant substrates to activation
of anticoagulant protein C, is recognized by thrombin mainly
through exosite I.62 Exosite II is especially important for
binding to platelet GpIbα, a component of the platelet receptor
complex. In the bound complex GpIbα then functions as a
cofactor and enhances cleavage of the platelet receptor PAR-1,
thus promoting platelet activation.86
The pharmacological mode of action of the indirect
thrombin inhibitors heparin and the LMWHs, as well as the
bivalent direct inhibitors derived from hirudin, i.e., all anti-
thrombin agents in current clinical use apart from the mono-
valent direct inhibitors argatroban (2) and dabigatran (4b), also
involves interactions with the thrombin exosites. Hirudins
(lepirudin, desirudin, bivalirudin) bind to both the catalytic
cleft and exosite I,87 whereas heparin and LMWH oligosac-
charide drugs interact with thrombin (and fXa) through exosite
II (Figure 5a,c).88 The anticoagulant activity of heparin
derivatives is due to their activity as cofactors for the serpin
antithrombin (which also inhibits other coagulation proteases).
Once the ternary thrombin−heparin−antithrombin complex is
formed, thrombin inhibition ensues due to blocking of the
thrombin active site by the so-called reactive center loop of
antithrombin.89
A number of allosteric thrombin inhibitors acting at the
exosites have been described, including aptamers targeting
either exosite. Some of these oligonucleotide agents have
undergone clinical development (reviewed in ref 90), although
none appear to have progressed. Ichorcumab is an antibody
being developed by Janssen;91 it is an agent derived from an
acquired antithrombin antibody isolated from a patient who
was identiﬁed upon screening for coagulation abnormalities
following a traumatic subdural hematoma.63 This antibody
was shown to interact with thrombin through exosite I
(Figure 5a,b) and to dose-dependently increase clotting time
in a thrombin time assay using human ex vivo blood, without
evidence of inhibition of thrombin catalytic activity in bio-
chemical assays. On the basis of the observation that the patient
in question remained free of bleeding complications for an
extended period, one might expect that ichorcumab (and
perhaps other exosite I modulators) may provide a much
wider anticoagulation versus bleeding therapeutic margin than
is the case with other antithrombin agents, although further
mechanistic and eﬃcacy studies with ichorcumab are required.92
Factor VII. Functions and Biomedical Rationale. FVII is
the key enzyme in the extrinsic coagulation pathway (Figure 1).
Upon vascular injury the membrane protein TF becomes
exposed on the vascular lumen, where it binds circulating
procoagulant fVII or fVIIa. Formation of the activated
TF−fVIIa complex then triggers the initiation of blood clotting
through proteolytic activation of fIX to fIXa and fX to fXa.93
It has been reported that mice lacking fVII succumb peri-
natally due to bleeding from normal blood vessels,94 whereas
mice genetically engineered to express very low levels of fVII
(∼0.7% of normal) live to adulthood but develop cardiac
ﬁbrosis.95 The International Registry on Congenital FVII
Deﬁciency (IRF7) Study Group has been collecting extensive
clinical data on fVII deﬁciency in people with rare bleeding
disorders, and overall there is no consistent correlation between
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bleeding symptoms and fVII levels, although surgery-related
bleeding is frequent.96 Compared to thrombin and fX deﬁciency,
people with fVII deﬁciency have comparatively fewer bleeding
events.97 Although severe bleeding phenotypes typically occur
for people with fVII coagulation activity of <2% of normal,98
some individuals with fVII activity of <1% do not manifest any
spontaneous or provoked bleeding, whereas many patients with
fVII coagulation levels of >5% have severe bleeding symptoms.99
Collectively, the mouse knockout studies and the informa-
tion available from fVII deﬁciency in humans suggest that thera-
peutic inhibition of fVIIa should be able to provide a margin
between antithrombotic and bleeding eﬀects. Studies with
several biological agents that suppress fVII activity (including
active site-inhibited fVIIa,100 anti-TF antibodies, and TF
mutants that bind fVII but form an enzymatically inactive
complex101) in animal models of thrombosis also show that
fVIIa inhibition can produce antithrombotic eﬀects without
severely disturbing hemostasis.
Inhibitor Design. Although a number of biologics targeting
fVII activity, and small-molecule direct inhibitors of fVIIa, had
been trialled in the past (reviewed in ref 102), none currently
remain in clinical development as far as can be ascertained.
The substrate-binding site of fVIIa adopts a diﬀerent overall
shape compared with other related proteases. The main sequence
diﬀerences are K192 (acidic or neutral residue in most proteases)
and an insertion at position 170 (compare Figure 2). As can
be observed in the experimental covalent complex between a
chloromethyl ketone inhibitor (12, Figure 7a), fVIIa displays
more extensive S2 and S3 sites compared to, for example,
thrombin and fXa, whereas the S4 site is comparatively shallow
and ill-deﬁned (Figure 7b).
The benzimidazole amidine compound 13 is an example
of a potent fVIIa inhibitor (Ki = 2 nM) with high selectivity
over most related proteases (including thrombin and fXa)
except PK. It was designed to make multiple polar interactions
with the fVIIa S2 site, including the comparatively unique K192
residue (Figure 7c), and is potentially suitable for once daily iv
administration in humans.103 The tetracyclic benzamidine 14
also interacts exclusively with the S1 and S2 sites of fVIIa,
including a salt bridge between its benzoate group with K192
and a hydrophobic interaction of the anisole group with a
small S2 hydrophobic pocket (Figure 7d). Compound 14 is
also highly potent (fVIIa Ki = 1.9 nM) and selective (>1000-
fold over thrombin, fXa, and trypsin) and was reported to show
eﬃcacy in a rabbit model of arterial thrombosis, with no signiﬁ-
cant prolongation of cuticle bleeding time.104 Unlike 13 and 14,
the peptidomimetic fVIIa inhibitor 15 (fVIIa IC50 = 93 nM and
>100-fold selective over thrombin)105 extends into the enlarged
S3 site of fVIIa, which undergoes further ligand-induced enlarge-
ment (biphenyl group, observe altered position of D170g region
in Figure 7e compared to, for example, Figure 7d).
Like the other fVIIa inhibitors discussed, the recently
reported macrocyclic carbamate 16 (fVIIa Ki = 1.4 nM, highly
selective over fXa, fXIa, thrombin, and trypsin but poorly
selective over PK, Ki = 36 nM)
106 also makes extensive inter-
actions with the large S2 (and to some extend the S3) site of
fVIIa (Figure 7f). Rather than a P1 benzamidine group, 16
contains an aminoisoquinoline, which is signiﬁcantly less basic
(1-aminoisoquinoline has a pKa of 7.27
108). However, per-
meability of macrocyclic compounds such as 16 was still
observed to be low but could be improved upon further
optimization109−111 to aﬀord derivatives of 16 with not only
improved permeability and oral bioavailability (up to 40% in
dog) but also selectivity over kallikreins.110
Factor IX. Functions and Biomedical Rationale. FIX is a
key enzyme in the ampliﬁcation of coagulation through the
intrinsic pathway. Autoactivation of fVII upon binding of TF
ultimately leads to the formation of thrombin, which feeds back
to activate fXI on the surface of platelets. FXIa then initiates
the intrinsic pathway by activating fIX, whose active form fIXa
cleaves fX to fXa, thus generating more thrombin and accelerating
ﬁbrin formation (Figure 1).
FIX deﬁciency is the cause of the X-linked hereditary
bleeding disorder hemophilia B, whereas hemophilia A results
from deﬁcient or defective fVIII. The severity of hemophilia B
is correlated with plasma fIX levels and spontaneous bleeding
occurs in individuals with <1% of normal fIX activity, whereas
bleeding occurs only as a result of injury or surgery in those
Figure 7. (a) Chemical structures of fVIIa inhibitors: 12, H-D-Phe-Phe-Arg-CH2Cl; 13, compound 9 from ref 103; 14, BMS-593214;
104 15,
compound 5 from ref 105; 16, compound 27a from ref 106. Complexes of inhibitors (green CPK sticks) with FVIIa (gray CPK surface) are shown:
12 (a; PDB code 1DAN107), 13 (b; PDB code 2B7D), 14 (c; PDB code 4ISH), 15 (d; PDB code 1WTG), and 16 (e; PDB code 5I46).
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with 1−5% fIX activity, and the tendency to bleed from small
wounds and during surgery decreases from patients with >5%
fIX activity to hemophilia B carriers, who display 60% of
normal median fIX activity.112
Inhibition of fIXa may be a good therapeutic strategy113
because the fVIIIa−fIXa complex mediates propagation of
coagulation upstream of the main thrombin-driven ampliﬁca-
tion at the fVa−fXa step and because fVIIIa−fIXa-catalyzed
activation of fX appears to be the rate-limiting step for
thrombin generation. Speciﬁc studies have shown that whereas
reduction of fIX levels by up to 99% results in acceptable levels
of bleeding, this provides a signiﬁcantly reduced risk of
thrombosis.114,115 Potential eﬃcacy and safety of anticoagula-
tion at the level of fIX is suggested by studies with genetically
engineered mice (reviewed in ref 116), and the safety aspect of
such a strategy is also indicated by a recent clinical gene therapy
study in people with severe hemophilia B, which showed
that bleeding episodes were suppressed upon expression of as
little as 1−6% of normal fIX.117 Furthermore, in another recent
study, in which a prototype small-molecule fIX inhibitor (20 in
Figure 8a) was compared with the fXa inhibitor apixaban
(23; Figure 9) using pharmacokinetics−pharmacodynamics
analysis, a larger therapeutic window between antithrombotic
and bleeding eﬀects was predicted for the fIX inhibitor 20
compared to 23.118
Inhibitor Design. There does not appear to be any small-
molecule fIXa inhibitor currently under clinical development,
although an oral fIXa inhibitory agent, TTP889 (structure not
disclosed), was trialled unsuccessfully some years ago.119
An early X-ray crystal structure of the catalytic domain of
fIXa with p-aminobenzamidine bound in the S1 site (Figure 8b)
shows a similar substrate-recognition site as is observed in
related Ser proteases, especially that of fXa, although the S3 and
S4 sites adopt a somewhat diﬀerent position and shape.120
Most fIXa inhibitors were originally developed by reengineering
fXa inhibitors; e.g., the oxadiazole 17 is an early redesigned fXa
inhibitor with 15-fold selectivity for fIXa over fXa.121 Its fIXa
binding mode shows (Figure 8c) the usual interactions of the
amidine function in the S1 site, with the phenyl substituent of
the oxadiazole ring occupying the S3 site, without extending
into the S4 site. In this compound fIXa selectivity probably is
derived from the interaction of the second phenyl group in an
induced subpocket (compare Figure 8b) next to the S1 site and
opposite the S3 site (sometimes referred to as the S1β site).
Another dual fIXa and fXa inhibitor (fIXa Ki = 13 nM but
130-fold selective for fXa over fIXa) is the pyrazolobenzamidine
18.122 It also binds into the S1β site (CF3 group), but here the
presumed fIXa selectivity gain from this interaction is counter-
acted by extension of the ligand into the conformationally
ﬂexible S4 site (benzimidazole group; Figure 8d) in a way
reminiscent of what is observed with selective fXa inhibitors
(see below).
An example of a more fIXa-selective compound is 19 (Ki =
2.4 nM and 210-fold selective over fXa), which makes only
peripheral interactions with the S1β site (whose cavity is
occupied by two crystallographically detectable water mole-
cules) and extends into the S4 site (triazole ring), this site
adopting a similar shape as in the uncomplexed form (compare
Figure 8e,b).123 Here the tetrazole group of the inhibitor
also makes favorable polar interactions with the S2 site, and
derivatives of 19 where the tetrazole is replaced with groups
capable of charge-reinforced H-bonds in this region were
reported to be even more fIXa-selective than 19.123 As discussed
in the thrombin and fXa sections, potent and selective inhibitors
lacking a strongly basic group for interactions in the S1 site have
been discovered, compound 19 is an analogous example of a fIXa
inhibitor. Despite the lack of strongly ionized groups, triazole-
containing compounds such as 19 were observed to lack
oral bioavailability.123 The structurally related compound 20
(fIXa Ki = 3.5 nM, 140-fold selective over fXa),
118 on the other
hand, is predicted to interact only with the S1−S3−S4 sites, but
here the carboxybenzimidazole group inserts deeply into the S4
cleft where it makes multiple favorable interactions (Figure 8f).
Factor X. Functions and Biomedical Rationale. The
extrinsic and intrinsic coagulation pathways converge on fX,
which is thus a key enzyme common to both pathways. FXa
associates with fVa to form prothrombinase, which converts
prothrombin to thrombin. FXa activity thus leads to blood clot
Figure 8. (a) Chemical structures of fIX inhibitors: 17, compound 16 from ref 121; 18, compound 3b from ref 122; 19, compound 82 from ref 123;
20, compound 1 from ref 118. (b) p-Aminobenzamidine (green CPK sticks) bound in fIXa (gray CPK surface; PDB code 1RFN120). Binding modes
of 17 (c; PDB code 3LC5), 18 (d; PDB code 1X7A), 19 (e; PDB code 5EGM), and 20 (f; likely fIXa-binding mode from docking to the 5EGM
receptor) in fIXa. All docking results shown in this and subsequent illustrations were generated using the Glide application within the Maestro
modeling suite (release 2016-2), Schrödinger, LLC, New York.
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formation and wound closure, whereas fX deﬁciency disturbs
hemostasis.
As is the case for prothrombin, fX deﬁciency is not
compatible with life and complete fX deﬁciency does not
occur in humans. In mice knockout of the F10 gene causes
partial embryonic lethality and animals that are born die from
neonatal bleeding.124 Mice with fX activity as low as 1−3%,
however, are viable with a mild bleeding diathesis.125 Inter-
national registries of fX-deﬁcient patients have been used to
classify the bleeding severity associated with fX deﬁciency:
at fX coagulation activity levels of <1% it is severe, at 1−5% it is
moderate, and at 6−10% it is mild, whereas levels of >20% are
not usually associated with bleeding.126
Indirect Inhibition. As mentioned in the thrombin section,
formation of a ternary thrombin−heparin−antithrombin com-
plex is necessary for heparins to block thrombin activity.
Unfractionated heparin has a polysaccharide chain suﬃciently
long to form a ternary complex with thrombin, unlike LMWHs,
which are too short to form this ternary complex and that are
thus unable eﬃciently to inhibit thrombin. However, both
heparin and LMWHs bind and activate antithrombin toward
fXa inhibition, thus acting as indirect allosteric fXa inhibitors.127
One such heparin derivative is the pentasaccharide fondaparinux,
the ﬁrst selective fXa inhibitor approved globally for the preven-
tion and treatment of thrombosis (ﬁrst approval in 2001).128
Fondaparinux is a parenteral agent that provided much of the
initial clinical validation of fXa as an antithrombotic drug target
that supported subsequent extensive eﬀorts to develop oral
direct fXa inhibitors, and fondaparinux remains in clinical use to
this date.
Inhibitor Design. The discovery of fXa active-site inhibitors
in many ways mirrors that of thrombin inhibitors, starting
from early covalent peptide inhibitors targeting the protease
S195 catalytic residue, progressing to reversible peptidomimetic
agents with basic substituents that engage the fXa S1 subsite,
and ﬁnally culminating with nonpeptidic, neutral, and orally bio-
available agents (reviewed in ref 129). In fact the ﬁrst such agent
(that is not a prodrug) approved for clinical use, rivaroxaban
(22; Figure 9a), was a fXa rather than a thrombin inhibitor.
Rivaroxaban was developed from high throughput fXa screen-
ing hits such as the tetrahydroisoindolediones 21 (fXa IC50 ≈
100 nM).47,130 It was originally thought that the charged
organophosphonium (21a) and acetimidamide (21b) sub-
stituents of these compounds acted as S1 ligands but sub-
sequent SAR and X-ray crystallography studies revealed that
in fact the chlorothienyl group present in both 21a and 21b
(and retained in 22 and many other fXa inhibitors) fulﬁlled this
function.47
Rivaroxaban (22) is a highly potent (fXa Ki = 0.4 nM),
selective (>20 000-fold with respect to IC50 values against a
Figure 9. (a) Chemical structures of representative small-molecule direct fXa inhibitors: 21a and 21b, compounds 1 and 2 from ref 47; 22,
rivaroxaban;130 23, apixaban;136 24, edoxaban;137 25, betrixaban;138 26, letaxaban;139 27, darexaban;140 28, eribaxaban;141 29, otamixaban;142 30,
DPC-423.143 (b) The Ser protease S pockets (labeled) in the substrate-binding site (gray CPK surface) of the uncomplexed active form of fXa
(PDB code 1C5M31) are shown, with a narrow channel (ﬂanked by Q61 and Q192, green surface) between the S1 and S1′ sites and a unique S4
pocket, lined by the aromatic residues Y99, F174, and W215 (green). (c) Complex between 22 and fXa (PDB code 2W26130). (d) Superposition of
the fXa-binding modes of 22 (cyan), 23 (green, PDB code 2P16),136 24 (yellow, modeled), 25 (salmon, modeled), 26 (gray, PDB code 3KL6),139
27 (orange, modeled), 28 (magenta, PDB code 2PHB),141 and 29 (blue, modeled). (e) Compounds such as 29 (magenta) and 30 (yellow; pose
from PDB code 3M36143) form the usual H-bonding interactions with the S1 residue D189 (yellow broken lines), whereas compounds such as 22
(gray) and 23 (cyan) make edge-to-face interactions with Y228. (f) FXa has A190, which is S190 in trypsin. The fXa-binding mode of for example,
23 (cyan) is not compatible with this altered pocket: observe the steric clash (green broken line) between S190 of trypsin (structure from PDB
code 3M35143 complex between 30 and trypsin) and the anisole methyl group of 23 (apixaban) upon structural superposition. Docked structures
were obtained using the 2W26 receptor.
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range of related Ser proteases),131 and orally bioavailable
(>60% in preclinical species and >80% in humans)47 com-
pound and is now the most widely used of the new DOACs.
Despite its comparatively short terminal half-life (6−9 h
in humans),132 22 can be used in once- or twice-daily oral
regimens in a number of licensed prevention (stroke and
systemic embolism in patients with AF, venous thromboemb-
olism after major surgery, recurrent venous thromboembo-
lism, atherothrombotic events in patients with acute coronary
syndrome) and treatment (deep vein thrombosis and
pulmonary embolism) indications.133 Apixaban (23)134 and
edoxaban (24)49 are also highly potent and selective fXa
inhibitors that were approved for similar indications more
recently. All three agents (22−24), as well as the thrombin
inhibitor dabigatran etexilate (4a; see above), are used widely
for the prevention of stroke in patients with AF, where the
choice of the best agent for individual patients is still a
developing area.135
A range of diﬀerent fXa inhibitors have been evaluated in
clinical trials, but none of these appear to have progressed.
Most recently betrixaban (25) did not perform signiﬁcantly
better than enoxaparin in terms of eﬃcacy in deep-vein
thrombosis and safety in terms of bleeding in a phase III
trial.144 This result followed on from another unsuccessful
phase II trial with darexaban (27), which, when added to
antiplatelet therapy after acute coronary syndrome, showed
no eﬃcacy but an increase in bleeding.145 Letaxaban (26),
eribaxaban (28), and otamixaban (29) are examples of other
fXa inhibitors that have been studied clinically.
The unique features of fXa that have been widely exploited in
the design of selective inhibitors are a narrow channel between
the S1 and S1′ sites and a unique S4 pocket (Figure 9a,b).
For example, in the complex between 22 and fXa the passage
between S1 and S1′ is obstructed through a rearrangement
(with respect to the uncomplexed structure) of the Q61
and Q192 side chains, which can be seen to interact through
H-bonds (Figure 9c). This has the eﬀect of precluding ligand
access to S1′−S4′ and partially occluding S2; similar features
are frequently observed in inhibitor−fXa complexes. All selec-
tive fXa inhibitors possess cyclic substituents (blue portions of
structures in Figure 9a) that can interact with the S4 site
by stacking between the aromatic residues Y99 and F174
(Figure 9d). The residues corresponding to Y99 and F174 in,
for example, thrombin are L99 and I174, and the S4 site thus
represents an important selectivity determinant between fXa
and thrombin. Structurally varied fXa inhibitors invariably
assume an “L”-shaped binding pose, where the short and long
legs of the L (red and blue, respectively, in Figure 9a) bind into
the S1 and S3−S4 pockets, respectively. As with thrombin
inhibitors, compounds possessing basic groups in the sub-
stituents that interact with S1, such as 29 and 30, form the
usual H-bonding interactions with D189 at the base of the
S1 site, whereas corresponding neutral substituents, such as
those in 22 and 23, make edge-to-face interactions with Y228
(Figure 9e). Unlike many other S1A proteases, fXa possesses an
Ala residue at position 190, and the fact that this residue is Ser
in, for example, trypsin can be exploited for selectivity design.
The presence of the S190 residue leads to a smaller volume of
Figure 10. (a) Chemical structures of fXIa inhibitors: 31, compound 33 from ref 153; 32, the closely related macrocyclic compound 16 from ref 154;
33, β-lactam covalent fXIa inhibitor related to clinical compound EP-7041 (compound 168 from ref 159) and structurally and mechanistically related
tryptase inhibitor BMS-262084 34;155 35, irreversible α-ketothiazole inhibitor (compound 11c from ref 157); 36 and 37, S1-binding fragments
elaborated into potent fXIa inhibitors such as 38 (compound 13 from ref 158). (b) FXIa (gray CPK surface) binding mode of 31 (cyan sticks),
showing interactions with the unique S1′ and S2′ subsites (labeled) of fXIa (PDB code 4X6P). (c) Likely covalent adduct formed between fXIa S195
catalytic residue and the β-lactam ring of 33 (modeled using covalent docking based on the 4X6P receptor). (d) Similar attack of the S195 alcohol
side chain on the α-ketothiazole of 35 leading to the covalent complex shown (PDB code 1ZPC). (e) Experimental binding pose of 38 in fXIa
(PDB code 4CRF). (f) Interactions of fragment 36 and (g) fragment 37 in the S1 subsite (PDB codes 4CR5 and 4CR9).
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the S1 pocket at its base in trypsin-like proteases. The
FXa-binding mode of many nonbasic inhibitors, e.g., 23, is not
compatible with this contracted pocket (Figure 9f).
Factor XI. Functions and Biomedical Rationale. Following
activation of the contact system fXIIa converts the zymogen fXI
to active fXIa, which then promotes coagulation via Ca2+-
dependent activation of fIX. People who lack fXI have a mild
trauma-induced bleeding disorder, referred to as hemophilia C,
but this is mainly restricted to tissues with high ﬁbrinolytic
activity. Even in individuals with severe fXI deﬁciency, serious
spontaneous bleeding is uncommon, whereas these individuals
have a high probability of postoperative hemorrhage; indi-
viduals with moderate levels and approaching the lower limit of
the normal range generally have a lower risk of postoperative
bleeding.146 This mild clinical phenotype is mirrored by fXI
deﬁciency mouse models, where it was observed that arterial
thrombus formation was severely impaired but was not asso-
ciated with excessive bleeding.147
These observations have led to the current belief that in vivo
coagulation is mediated almost exclusively by the extrinsic
rather than the intrinsic pathway.148 Whereas fXIa appears to
be dispensable for hemostasis, it clearly plays an important role
in thrombosis, possibly through the thrombin−fXIa feedback
loop (Figure 1). This is indicated by the ﬁndings that f XI−/−
mice appear to be protected from carotid artery thrombus
formation in a FeCl3-induced thrombosis model and that
reconstitution of these animals with human fXI resolved
resistance to thrombus formation.147 Proof of concept for
fXIa as a potentially valuable thrombosis drug target in







m5rU DNA, now being developed by Bayer and Ionis
Pharmaceuticals as BAY 2306001 and IONIS-FXIRx150). In a
clinical study with this agent it was found that postoperative
venous thromboembolism could be prevented eﬀectively by
lowering fXI levels in patients undergoing knee arthroplasty
and treatment appeared to be safe with respect to the risk of
bleeding.151
Inhibitor Design. Although a number of advanced small-
molecule direct fXIa inhibitors have been reported (reviewed in
ref 152), currently the only clinical experimental drug with this
mechanism is EP-7041 (structure not disclosed, probably related
to 33 in Figure 10; ClinicalTrials.gov identiﬁer NCT02914353),
which is being developed by eXIthera Pharmaceuticals as a
parenteral agent.
Compared to most other Ser proteases, fXIa possesses a
comparatively open S2−S1′−S2′ binding region and most
selective fXIa inhibitors for which experimental complexes are
available can be observed to occupy this region, especially the
S1′ site (Figure 10). Compounds such as 31 and its macrocyclic
derivative 32 are highly potent and selective (e.g., fXIa Ki =
0.16 nM and 100-fold selectivity over PK and higher over a
range of related proteases for 32) but possess little oral
bioavailability.153,154 Covalent inhibitors are also known, e.g.,
β-lactams such as 33, which presumably (Figure 10c) form similar
covalent protein adducts as is known to occur with structurally
related protease (tryptase and trypsin) inhibitors such as
34.155,156 Diﬀerent irreversible fXIa inhibitors are also known,
e.g., the α-ketothiazole compound 35 (fXIa IC50 = 0.12 μM),
157
whose covalent protein adduct structure has been determined
experimentally (Figure 10d). This compound not only occupies
the S1, S1′, and S2 sites but also makes hydrophobic inter-
actions with the S4 site, which assumes a diﬀerent shape than
the S4 sites observed in other fXIa complexes.
Fragment-based design has also been applied to the discovery
of fXIa inhibitors.158 By use of a screening cascade comprising
biophysical (NMR, surface plasmon resonance, and X-ray crystal-
lography) and biochemical assays, a number of S1-binding
fragments such as 36 and 37 (high μM to mM aﬃnity;
Figure 10f,g) were identiﬁed, which were then elaborated into
potent fXIa inhibitors such as the quinolinone 38 (Figure 10e),
with a very similar binding mode to 31 (Figure 10b). Com-
pound 38 was found to be highly potent (fXIa Ki = 0.5 nM)
and selective (again PK was the only oﬀ-target Ser protease,
10-fold higher Ki) but showed low permeability (CaCo-2 Papp <
0.28 × 10−6 cm·s−1).158
Factor XII. Functions and Biomedical Rationale. The
zymogen fXII can be activated in a number of ways.160 This can
occur by slow autoproteolysis or more eﬃciently by the action
of PK upon surface-bound fXII to form the disulﬁde-tethered
heavy (50 kDa) and light (30 kDa) chains of α-fXIIa.161
This form of fXIIa then propagates the intrinsic coagulation
pathway by activating fXI and reinforces the KKS by further
activating prekallikrein. α-FXIIa can then be further cleaved by
PK to form β-fXIIa, a 30-kDa fragment that contains the cata-
lytic light chain and the C-terminal peptide of the heavy chain
of α-fXIIa. β-FXIIa, which retains catalytic activity for prekal-
likrein but not fXI, is released from the activating surface as it
has lost the portions of the heavy chain that mediate binding to
other proteins and to surfaces. Apart from prekallikrein and fXI
activation, fXIIa can also activate a range of diﬀerent substrates,
including the C1 esterase of the complement pathway, plas-
minogen, the uPA receptor of endothelial cells, and fVII.162,163
FXII-deﬁcient mice were found to be protected against
arterial thrombosis, collagen- and epinephrine-induced throm-
boembolism, and ischemic stroke.164,165 In all these in vivo
models, such protection was abolished by infusion of human
fXII into fXII-null mice. Pharmacological target validation of
fXIIa as a potential thrombosis drug target has also been
provided with anti-fXIIa antibodies that provided thrombopro-
tection without increasing bleeding risk in animal models
(including primates) of thrombosis,166−168 as well as with rHA-
infestin-4, a recombinant fusion protein between infestin-4
derived from Triatoma infestans, a blood-feeding insect, and
human albumin, which was shown to improve outcomes in a
rodent model of ischemic stroke.169
FXIIa-mediated activation of the intrinsic coagulation pathway
has also recently been linked to Alzheimer’s disease (AD).170,171
It is believed that amyloid β can activate fXII directly or
indirectly and that subsequent vessel occlusion and inﬂammation
may contribute to cognitive decline in AD. FXIIa inhibitors may
therefore oﬀer a new treatment modality in neurodegenera-
tion.172,173
Inhibitor Design. Apart from certain nonselective Ser
protease inhibitors such as 39 (Figure 11a,c) and a number
of high throughput fXIIa screening hits,174 which do not appear
to have been followed up, there are currently no known drug-
like small-molecule fXIIa inhibitors. Structure-based design of
such inhibitors is diﬃcult because little is currently known
about the active conformation of fXIIa (Figure 11b). Homology
models (Figure 11c) suggest that fXIIa has the usual S1 subsite
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but that S1′, S2, S3, and S4 sites are more extensive than the
corresponding sites observed in other Ser proteases.
Certain coumarin derivatives were recently reported as
selective fXIIa inhibitors, although their potency is modest.
For example, derivative 40 (fXIIa IC50 = 5 μM) probably binds
to fXIIa as shown in Figure 11e, engaging the S1 and S2
sites.175 It is likely that these compounds are suicide inhibitors
that form covalent adducts with the enzyme: the modeled
bound pose places the pyrone ring of 40 in the vicinity of the
catalytic S195, and one can imagine that nucleophilic attack of
the Ser hydroxyl on the pyrone ring may ensue from the initial
binding pose.
Very potent and highly selective peptide inhibitors of fXIIa
have been reported.176−178 These macrocyclic peptides were
identiﬁed by selection against fXIIa binding and inhibition of
phage-displayed peptide libraries of the form Cys-(Xaa)n-Cys-
(Xaa)n-Cys, cyclized by reaction of the Cys thiol functions with
trifunctional reagents such as 1,3,5-triacryloyl-1,3,5-triazinane in
the case of 41 (Figure 11a,f). Some of the fXIIa-inhibitory
peptides displayed high potency (low to sub-nM Ki for fXIIa)
and selectivity, as well as good plasma stability and the ability
to block the activation of the intrinsic coagulation pathway in
ex vivo human blood.
Plasma Kallikrein. Functions and Biomedical Rationale.
Although here we only discuss plasma kallikrein (PK, KLKB1),
this enzyme is actually part of the larger kallikrein family that
also contains the functionally and structurally related182 tissue
kallikreins KLK1−KLK15. The tissue kallikreins are now beginning
to be pursued as potential drug targets in a range of disorders,
especially respiratory, cardiovascular, and dermatological
diseases, as well as in cancer (reviewed in ref 183).
The zymogen of PK is prekallikrein, which circulates in the
blood as a complex with HK. This zymogen is activated to PK
by α-fXIIa on negatively charged surfaces (contact activation in
pathobiological situations), by β-fXIIa in plasma,184 and by
prolylcarboxypeptidase on endothelial cells.185 PK can activate
the intrinsic pathway of coagulation through reciprocal acti-
vation of fXII, the KKS through cleavage of HK to generate
bradykinin, the ﬁbrinolytic system through activation of prouro-
kinase and plasminogen, and the complement system via
formation of β-fXIIa (reviewed in ref 13).
With roles in coagulation, ﬁbrinolysis, and inﬂammation, PK
has been proposed as a potential drug target in several diseases
(reviewed in ref 186). Like other components of the contact
activations system such as fXII (see above) and HK, congenital
deﬁciency of prekallikrein in humans usually causes no bleeding
or other health problems but manifests in long aPTT.187
Similarly, PK-deﬁcient mice (KLKB1−/−) show increased aPTT
but without prolonged bleeding time.188
Inhibitor Design. In the past several peptide-based (including
42a and unrelated bicyclic peptides with high potency and
selectivity for PK)189 and small-molecule direct PK inhibitors
(Figure 12) have been reported. Some were evaluated in animal
models of thrombosis, and the results from such studies suggest
that PK inhibition may be a tractable anticoagulation strategy
that provides a safety margin between antithrombotic and
bleeding eﬀects (reviewed in ref 186). However, no small-
molecule direct PK inhibitors are currently under clinical trials
as antithrombotics.
Figure 11. (a) Chemical structures of fXIIa inhibitors: 39, NAPAP; 40, coumarin derivative 23 from ref 175; 41, bicyclic tridecapeptide 61 from ref 176.
(b) Currently available X-ray crystal structures of fXII (gray CPK surface) are of catalytically inactive conformations: although the catalytic residues
S195, H57, and D102 (stick models) are positioned correctly, the oxyanion hole between the amino groups of G193 and S195 (broken line) is absent
and the substrate binding pockets are incompletely formed (PDB code 4XDE179). (c) A homology model of fXIIa (similar to that described in ref 175
based on the inactive conformations of fXII and the known active conformation (1YC0180) of hepatocyte growth factor activator, the Ser protease most
closely related to fXII, displays a fully formed S1 pocket and is consistent with binding of 39 (green CPK sticks)-derived compounds with known fXIIa-
inhibitory activity.181 The modeled binding mode is similar to that observed in the experimental binding mode of 39 in thrombin (d; PDB code
1DWD67). (e) Coumarin 40 (cyan CPK sticks) is likely to bind to fXIIa as shown.175 (f) Highly potent and selective conformationally constrained
peptide inhibitors of fXIIa have recently been reported, e.g., 41 (green CPK sticks; polar interactions with fXIIa as yellow broken lines) in a modeled
bound conformation (according to ref 176).
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PK Inhibitors in Perioperative Bleeding. Since PK plays a
role in activation of both coagulation and ﬁbrinolysis pathways,
PK inhibitors may paradoxically display pro- or anticoagulant
activity, depending on pathological context. Small-molecule PK
inhibitors are also potentially attractive for the treatment of
bleeding during cardiac surgery and cardiopulmonary bypass,
since coagulation, ﬁbrinolysis, and inﬂammation all play
a role in these indications. Aprotinin (bovine pancreatic trypsin
inhibitor) and ecallantide (a recombinant peptide) are Kunitz-
type Ser protease inhibitors. Aprotinin inhibits PK, as well as a
number of other Ser proteases (including plasmin and
thrombin).195 This agent had been in successful clinical use
to reduce blood loss and the need for transfusion associated
with heart surgery. Aprotinin was withdrawn in 2007, but
marketing authorization was reinstated in 2013 in the European
Union.196 Ecallantide, on the other hand, is a selective PK inhib-
itor and is currently approved for the treatment of hereditary
angioedema.197 This agent has also been trialled in surgical
blood loss indications in comparison with the plasmin inhibitor
tranexamic acid but was found to be less eﬀective than
tranexamic acid.198 This result may indicate that combined PK
and plasmin inhibition is desirable to prevent perioperative
bleeding. The small-molecule direct dual PK and plasmin
inhibitor 45 (Figure 12a,e), was evaluated in a phase II study in
patients undergoing coronary artery bypass grafting with
cardiopulmonary bypass and was found to reduce chest tube
drainage and transfusions.199 However, a subsequent multi-
center study was terminated due to unexpected patient safety
issues.200 Whether or not these were associated with the
incomplete protease selectivity of 45, which apart from PK
(Ki = 0.02 nM) and plasmin (Ki = 2.2 nM) also inhibits fXa
(Ki = 45 nM) and fXIa (Ki = 18 nM),
201 is not clear.
PK Inhibitors in Ophthalmic Indications. Drugs targeting
vascular endothelial growth factor (VEGF) signaling are
currently used to treat loss of vision associated with macular
edema and retinal vein occlusion.202 VEGF-induced macular
edema occurs as a result of increased retinal vascular per-
meability, which in turn allows inﬂux of plasma components,
including those of the KKS. This system is believed to mediate
many of the inﬂammatory aspects of diabetic retinopathy, and
the enzymatic activity of PK, which produces bradykinin from
HK, is important in these processes.203 KalVista Pharmaceut-
icals is currently developing a PK inhibitor (KVD001, structure
not disclosed) as an intravitreal agent in subjects with diabetic
macular edema (ClinicalTrials.gov identiﬁer NCT02193113).
KalVista originally acquired PK inhibitors from Vantia Thera-
peutics,204 and a recent report including authors from Vantia
showed that VEGF-induced retinal vascular permeability and
retinal thickening in KLKB1−/− mice were reduced signiﬁcantly
in comparison to wild-type animals upon systemic admin-
istration of VA999272, a compound with high potency and
selectivity for PK versus tissue kallikrein (KLK1) and a number
of other related Ser proteases.205 It is not clear if VA999272 and
KVD001 refer to the same compound structure.
Plasmin. Functions and Biomedical Rationale. Under
hemostatic conditions ﬁbrinolysis is required in order to
Figure 12. Progress has recently been made in the understanding of the structural biology of PK with the aid of cyclic peptides such as pkalin-3 (42a in
panel a).27 This cyclic decapeptide, which is selective for PK, was identiﬁed through re-engineering of a related peptide (42b in panel a), mupain-1−16,
which is selective for uPA. The complexes of 42a with PK and 42b with murine uPA are shown in panel b (PDB code 4ZJ627) and panel c (PDB code
4X1N190), respectively. In both complexes the side chain of the ligand L-3-(N-amidino-4-piperidinyl)alanine (Apa6) residue is bound in the S1 site.
uPA contains a lengthened 97-loop compared to PK, and the presence of an Arg (R217) residue in uPA (E217 in PK) renders the S2 and S3 sites
signiﬁcantly diﬀerent between the two proteases. This was exploited by replacement of Y4 and F5 in 42b with R4 and F5 in 42a. An additional
diﬀerence occurs in the S3′ site, where PK contains V35 instead of the R35 residue in uPA. This diﬀerence was exploited by replacement of Y7 and D9
in 42b with A7 and W9 in 42a. Comparison of the complexes of PK with 42a (b) and benzamidine (d; PDB code 2ANY191) shows that overall the
substrate-binding sites are similar with comparatively little induced ﬁt in the complex with 42a. Peptidomimetic (kallistop, 43;192 MDCO-2010, 45193)
and nonpeptidic (PF-04886847, 44194) PK inhibitors are also known, and a likely PK binding mode for 43 (based on docking to the 4ZJ6 receptor) is
shown in panel e. This compound makes many similar contacts with PK as the peptide 42a and additionally forms polar interactions between the ligand
benzoic acid group and the K147 residue. (f) The pharmacophoric similarity between the small-molecule PK inhibitors is evident from ﬂexible
alignment of 43 (magenta) and 44 (cyan) with the modeled bioactive conformation of 45 (green).
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prevent excessive clot formation. This process if self-regulated
at the level of ﬁbrin, which binds plasminogen, the circulating
plasma zymogen of plasmin, as well as tPA. The activity of tPA
is enhanced signiﬁcantly upon binding to ﬁbrin, and together
with uPA, tPA activates plasminogen to plasmin. Plasmin then
cleaves ﬁbrin and activates tPA and uPA in a positive feedback
loop. Because plasmin prefers a Lys residue at the P1 position
in its substrates, the action of plasmin generates soluble ﬁbrin
degradation products with C-terminal Lys residues. The Kringle
domains of both plasminogen and tPA contain Lys-binding
sites, leading to further recruitment of plasminogen and uPA to
ﬁbrin, thus enhancing plasmin formation and ﬁbrin cleavage.206
Increased ﬁbrinolysis occurs in some forms of disseminated
intravascular coagulation, in chronic liver disease, and in some
leukemias and is frequently induced upon major cardiac
surgery.207 Furthermore, pathological plasmin generation can
also occur during, for example, chronic inﬂammation and tumor
metastasis.208
Inhibitor Design. Plasmin inhibitors derived from the amino
acid lysine, such as 6-aminohexanoic acid and tranexamic acid,
are commonly used as antiﬁbrinolytic agents. These compounds
block plasmin activity indirectly by engaging Lys-binding sites in
the Kringle domain of plasminogen, thus preventing tPA- and
uPA-mediated conversion of plasminogen to plasmin. Apart from
broad-spectrum Ser protease inhibitors such as aprotinin
(refer to PK section), there are currently no reversible active-
site directed plasmin inhibitors approved or under clinical evalu-
ation, although such agents would be desirable for improved
antiﬁbrinolysis treatments and other indications where plasmin
activity is implicated.
Numerous plasmin inhibitors have been described (reviewed
in ref 208), but development has not progressed as far as for
other Ser proteases discussed here, although structural
selectivity rationales and medicinal chemistry starting points
are available (Figure 13). The main structural diﬀerence
between plasmin and its closely related Ser proteases is a
six-residue deletion (with respect to chymotrypsin; Figure 2)
and hence absence of the conserved 99-β-hairpin loop,209
resulting in a very extensive S4 site. The dual PK and plasmin
inhibitor (45) discussed in the PK section is likely to bind to
plasmin in a diﬀerent conformation (Figure 13b) than to PK
(Figure 12e). In plasmin the bulk of the inhibitor occupies the
S4 site and forms a polar interaction from the benzoate group
to the guanidine of R175. The most potent and selective plasmin
inhibitors reported to date are macrocyclic benzamidine
compounds such as 46 (Figure 13c), which are predicted to
make extensive interactions with the unique S4 site of plasmin
(Figure 13d). Compound 46a was reported to inhibit plasmin
with a Ki value of 0.68 nM and to be highly selective over
a range of Ser proteases, except trypsin, over which it is
moderately selective (100-fold).210
Like thrombin (Figure 5), fX, and fXI, plasmin contains a
cationic exosite II that recognizes heparin, which is known to
modulate plasmin activity allosterically.211 It has been shown
recently that certain dimeric sulfated polyphenols (termed
nonsaccharide glycosaminoglycan mimetics) selectively bind to
the plasmin exosite II, inhibit plasmin catalytic activity, and
block clot lysis in vitro.212
Activated Protein C. Functions and Biomedical Rationale.
Under hemostatic conditions blood clotting is held in check
through anticoagulant mechanisms, in which protein C plays
a dominant role. The circulating protein C zymogen is con-
verted to aPC by thrombin upon association with the cell
membrane receptors thrombomodulin and endothelial protein
C receptor. In this process the procoagulant activity of thro-
mbin is suppressed, since its exosite I, which otherwise engages
procoagulant thrombin-binding proteins, is occupied by
thrombomodulin. aPC, whose activity is further enhanced by
the cofactor protein S, exerts its anticoagulant activity predo-
minantly at the levels of fVa and fVIIa, which are degraded
through proteolytic activity of aPC. These proteases form part
of the prothrombinase (fXa−fVa) and tenase (fIXa−fVIIIa)
complexes, which in the absence of aPC activate prothrombin
and fX, respectively (Figure 1).19
As discussed earlier, thrombin generation is impaired in
the common recessive X-linked genetic disorders hemophilia
A and B, as well as the rare autosomal genetic disorder
parahemophilia, due to deﬁciencies in functional fVIII, fIX,
and fV, respectively. Most cases of hemophilia A and B are
severe and require preventive treatment, which currently involves
predominantly the use of octocog alfa (hemophilia A) or
nonacog alfa (hemophilia B), i.e., engineered versions of the
deﬁcient clotting factors fVIII and fIX, but the economic
burden of these treatments on healthcare systems is high.214
For this reason alternative strategies for the preventative treat-
ments of hemophilia A and B are sought,26 and one potential
approach is to enhance the lifetime of the prothrombinase
complex through inhibition of aPC catalytic activity, which
should enhance procoagulant activity. The potential safety of
this approach is indicated by the ﬁndings that while individuals
Figure 13. (a) The substrate-recognition site of plasmin (gray CPK surface) presents a signiﬁcantly diﬀerent shape compared to other Ser proteases,
as can be seen from an experimental complex with the covalent inhibitor H-Glu-Gly-Arg-CH2Cl (green CPK sticks), which forms an adduct with the
catalytic residues H57 and S195 (gray CPK sticks) and in which the Glu side chain of the inhibitor projects into the extensive and comparatively ﬂat
S4 site (PDB code 1BUI213). (b) Modeled (docking against 1BUI receptor) binding mode of 45 (Figure 12a). (c) Macrocyclic benzamidine plasmin
inhibitor compounds 46 (46a, compound 4 from ref 210; 46b, compound 8 from ref 210). (d) Predicted plasmin binding modes (modeled poses
from ref 210) of 46a (green) and 46b (cyan).
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with resistance to aPC, protein S deﬁciency, or protein C
deﬁciency are at increased risk of thromboembolic disease,
many remain asymptomatic and do not have a substantially
increased risk of thrombosis.215
Inhibitor Design. Using peptidomimetic aPC inhibitors
based on the scissile fV substrate sequence, it was shown
that such compounds could restore thrombin generation in
TF-triggered contact pathway-inhibited fresh blood from hemo-
philia patients.216,217 The ﬁrst small-molecule aPC inhibitor to
be reported is the benzamidine derivative 47 (Figure 14a),
which inhibits aPC with an IC50 value of 0.8 μM, is ∼60-fold
selective over thrombin, and signiﬁcantly restored thrombin
generation in hemophiliac plasma.218 More recently benzami-
dines such as 48 were described, with similar potency (aPC
IC50 = 0.9 μM for 48) as 47 but better-deﬁned selectivity (over
thrombin, fXa, and fXIa).219
Allosteric aPC inhibitors have also recently been reported.220
These were discovered using structure-based virtual screening
Figure 14. (a) Chemical structures of aPC inhibitors: 47, compound 1 in ref 218; 48, compound 29 in ref 219. The only X-ray crystal structure of
aPC (b; protein surface in gray CPK and catalytic resides as sticks) is one of a complex (PDB code 1AUT221) with 1 (green CPK sticks). A likely
binding mode of 48 in aPC (based on docking to the 1AUT receptor) is shown in panel c. Superposition of the aPC-docked conformation of 48
onto an aPC-aligned structure of thrombin (d; PDB code 1PPB66) shows that the ethylpiperidine group of 48 occupies the wide S2 subsite in aPC
(c), which is not consistent with binding to thrombin (d), which possess a 60-loop insertion (refer thrombin section). FV-binding exosite of aPC
(cyan CPK surface in panel e).
Figure 15. S1A proteases diﬀer in shape, hydrophobicity (a; surface coloring based on the normalized consensus hydrophobicity scale of amino
acids230 from least hydrophobic (pure white for Arg) to most hydrophobic (dark red for Ile)), and electrostatic potential (b; surface coloring from
most negative (dark red) to most positive (dark blue), calculated using the APBS program231). Shown are views into the substrate-binding site of
representative S1A protease structures from superpositions of PDB entries 1PPB (thrombin),66 2FIR (fVIIa),232 1RFN (fIXa),120 1C5M (fXa),31
1ZPC (fXIa),157 5TJX (PK),233 and 1BUI (plasmin).213
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and are thought to block an exosite adjacent to the catalytic site
and known to be involved in the recognition of fV. Although
the compounds have modest aﬃnity for aPC (high μM
Kd values), they were shown to suppress aPC-mediated fVa
inactivation in vitro.
■ CONCLUSIONS
As we have seen, structure-based design has played a major role
in the discovery of protease inhibitors, but rational design of
selectivity remains challenging. In some cases unique features in
the substrate-recognition sites of diﬀerent proteases have been
exploited successfully, but conformation ﬂexibility and selection
that are known to be responsible in large measure for protease
substrate selectivity are also evident in the case of small-
molecule inhibitor selectivity.75,222 A comparison of represen-
tative complex structures of S1A proteases in terms of
substrate-binding site hydrophobicity (Figure 15a) and electro-
static potential (Figure 15b) shows that these enzymes diﬀer
not only in their shape but also as far as their respective surface
polarity is concerned. These diﬀerences are evident in all
subsites of the binding site, even the well-conserved S1 pocket,
and are frequently evident from 3D protein structure com-
parisons but not necessarily from enzyme substrate speciﬁcity
diﬀerences alone.33,223 On the basis of the extensive structural
biology information that has been amassed, it can be expected
that highly selective inhibitors for many of the S1A proteases
can be designed. Such compounds not only will have potential
uses as speciﬁc and safe new drugs as we have discussed in the
individual sections above but will also help to unravel the
complex biology of the regulatory processes that these enzymes
are involved in.
Despite the improved utility in terms of predictability of
pharmacokinetics and pharmacodynamics of the current
DOACs that target thrombin and fXa, these are still associated
with signiﬁcant bleeding risks when compared with warfarin.51
It is hoped that new agents targeting components of the
coagulation cascade upstream of thrombin and fXa will
provide anticoagulation with fewer bleeding complications.54
In the meantime reversal agents for the DOACs are being
developed.224,225 Traditional indirect anticoagulants have well
established antidotes, e.g., protamine sulfate in the case of
heparin and vitamin K-containing preparations in the case of
VKAs.226 However, these antidotes do not reverse the eﬀects of
DOACs, whose use without antidote is therefore associated
with a certain risk in cases of spontaneous or trauma-induced
bleeding, as well as in the case of overdosing. This risk is
exacerbated by the comparatively long half-lives (7−17 h) of
DOACs.36 Although there is debate regarding the importance
of reversal agents for these drugs, the current lack of reversal
agents prevents wider use of DOACs.224 At present the only
approved DOAC reversal agent is idarucizumab, an antibody
fragment that binds and neutralizes both free and thrombin-
bound dabigatran (4b).227 Andexanet alfa is a modiﬁed and
inactivated form of fX speciﬁcally designed to reverse the anti-
coagulant activity of both direct and indirect fXa inhibitors.228
This reversal agent is currently in late-stage development.229
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A.; Konigsberg, W. H.; Nemerson, Y.; Kirchhofer, D. The crystal
structure of the complex of blood coagulation factor VIIa with soluble
tissue factor. Nature 1996, 380, 41−46.
(108) Zielinski, W.; Kudelko, A. Acid-base interactions in some
isoquinoline and quinazoline amino derivatives. ARKIVOC 2005, 66−
82.
(109) Richter, J. M.; Cheney, D. L.; Bates, J. A.; Wei, A.; Luettgen, J.
M.; Rendina, A. R.; Harper, T. M.; Narayanan, R.; Wong, P. C.;
Seiffert, D.; Wexler, R. R.; Priestley, E. S. Design and synthesis of novel
meta-linked phenylglycine macrocyclic FVIIa inhibitors. ACS Med.
Chem. Lett. 2017, 8, 67−72.
(110) Zhang, X.; Glunz, P. W.; Johnson, J. A.; Jiang, W.; Jacutin-
Porte, S.; Ladziata, V.; Zou, Y.; Phillips, M. S.; Wurtz, N. R.; Parkhurst,
B.; Rendina, A. R.; Harper, T. M.; Cheney, D. L.; Luettgen, J. M.;
Wong, P. C.; Seiffert, D.; Wexler, R. R.; Priestley, E. S. Discovery of a
highly potent, selective, and orally bioavailable macrocyclic inhibitor of
blood coagulation factor VIIa-tissue factor complex. J. Med. Chem.
2016, 59, 7125−7137.
(111) Ladziata, V.; Glunz, P. W.; Zou, Y.; Zhang, X.; Jiang, W.;
Jacutin-Porte, S.; Cheney, D. L.; Wei, A.; Luettgen, J. M.; Harper, T.
M.; Wong, P. C.; Seiffert, D.; Wexler, R. R.; Priestley, E. S. Synthesis
and P1′ SAR exploration of potent macrocyclic tissue factor-factor
VIIa inhibitors. Bioorg. Med. Chem. Lett. 2016, 26, 5051−5057.
(112) Plug, I.; Mauser-Bunschoten, E. P.; Broecker-Vriends, A. H. J.
T.; van Amstel, A. H. K. P.; van der Bom, J. G.; van Diemen-Homan,
D.-H. J. E. M.; Willemse, J.; Rosendaal, F. R. Bleeding in carriers of
hemophilia. Blood 2006, 108, 52−56.
(113) Eikelboom, J. W.; Zelenkofske, S. L.; Rusconi, C. P.
Coagulation factor IXa as a target for treatment and prophylaxis of
venous thromboembolism. Arterioscler., Thromb., Vasc. Biol. 2010, 30,
382−387.
(114) Sramek, A.; Kriek, M.; Rosendaal, F. R. Decreased mortality of
ischaemic heart disease among carriers of haemophilia. Lancet 2003,
362, 351−354.
(115) Darby, S. C.; Kan, S. W.; Spooner, R. J.; Giangrande, P. L.; Hill,
F. G.; Hay, C. R.; Lee, C. A.; Ludlam, C. A.; Williams, M. Mortality
rates, life expectancy, and causes of death in people with hemophilia A
or B in the United Kingdom who were not infected with HIV. Blood
2007, 110, 815−825.
(116) Monahan, P. E. Factor IX: insights from knock-out and
genetically engineered mice. Thromb. Haemostasis 2008, 100, 563−
575.
(117) Nathwani, A. C.; Reiss, U. M.; Tuddenham, E. G.; Rosales, C.;
Chowdary, P.; McIntosh, J.; Della Peruta, M.; Lheriteau, E.; Patel, N.;
Raj, D.; Riddell, A.; Pie, J.; Rangarajan, S.; Bevan, D.; Recht, M.; Shen,
Y. M.; Halka, K. G.; Basner-Tschakarjan, E.; Mingozzi, F.; High, K. A.;
Allay, J.; Kay, M. A.; Ng, C. Y.; Zhou, J.; Cancio, M.; Morton, C. L.;
Gray, J. T.; Srivastava, D.; Nienhuis, A. W.; Davidoff, A. M. Long-term
safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J.
Med. 2014, 371, 1994−2004.
(118) Ankrom, W.; Wood, H. B.; Xu, J.; Geissler, W.; Bateman, T.;
Chatterjee, M. S.; Feng, K.-I.; Metzger, J. M.; Strapps, W. R.; Tadin-
Strapps, M.; Seiffert, D.; Andre, P. Preclinical and translational
evaluation of coagulation factor IXa as a novel therapeutic target.
Pharmacol. Res. Perspect. 2016, 4, e00207.
(119) Eriksson, B. I.; Dahl, O. E.; Lassen, M. R.; Ward, D. P.;
Rothlein, R.; Davis, G.; Turpie, A. G. G. Partial factor IXa inhibition
with TTP889 for prevention of venous thromboembolism: an
exploratory study. J. Thromb. Haemostasis 2008, 6, 457−463.
(120) Hopfner, K.-P.; Lang, A.; Karcher, A.; Sichler, K.; Kopetzki, E.;
Brandstetter, H.; Huber, R.; Bode, W.; Engh, R. A. Coagulation factor
IXa: the relaxed conformation of Tyr99 blocks substrate binding.
Structure 1999, 7, 989−996.
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.7b00772
J. Med. Chem. XXXX, XXX, XXX−XXX
T
(121) Wang, S.; Beck, R.; Burd, A.; Blench, T.; Marlin, F.; Ayele, T.;
Buxton, S.; Dagostin, C.; Malic, M.; Joshi, R.; Barry, J.; Sajad, M.;
Cheung, C.; Shaikh, S.; Chahwala, S.; Chander, C.; Baumgartner, C.;
Holthoff, H.-P.; Murray, E.; Blackney, M.; Giddings, A. Structure
based drug design: development of potent and selective factor IXa
(FIXa) inhibitors. J. Med. Chem. 2010, 53, 1473−1482.
(122) Smallheer, J. M.; Alexander, R. S.; Wang, J.; Wang, S.;
Nakajima, S.; Rossi, K. A.; Smallwood, A.; Barbera, F.; Burdick, D.;
Luettgen, J. M.; Knabb, R. M.; Wexler, R. R.; Jadhav, P. K. SAR and
factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
Bioorg. Med. Chem. Lett. 2004, 14, 5263−5267.
(123) Meng, D.; Andre, P.; Bateman, T. J.; Berger, R.; Chen, Y.-H.;
Desai, K.; Dewnani, S.; Ellsworth, K.; Feng, D.; Geissler, W. M.; Guo,
L.; Hruza, A.; Jian, T.; Li, H.; Metzger, J.; Parker, D. L.; Reichert, P.;
Sherer, E. C.; Smith, C. J.; Sonatore, L. M.; Tschirret-Guth, R.; Wu, J.;
Xu, J.; Zhang, T.; Campeau, L.-C.; Orr, R.; Poirier, M.; McCabe-Dunn,
J.; Araki, K.; Nishimura, T.; Sakurada, I.; Hirabayashi, T.; Wood, H. B.
Development of a novel tricyclic class of potent and selective FIXa
inhibitors. Bioorg. Med. Chem. Lett. 2015, 25, 5437−5443.
(124) Rosen, E. D. Gene targeting in hemostasis. Factor X. Front.
Biosci., Landmark Ed. 2002, 7, d1915−1925.
(125) Tai, S. J.; Herzog, R. W.; Margaritis, P.; Arruda, V. R.; Chu, K.;
Golden, J. A.; Labosky, P. A.; High, K. A. A viable mouse model of
factor X deficiency provides evidence for maternal transfer of factor X.
J. Thromb. Haemostasis 2008, 6, 339−345.
(126) Brown, D. L.; Kouides, P. A. Diagnosis and treatment of
inherited factor X deficiency. Haemophilia 2008, 14, 1176−1182.
(127) Hirsh, J.; Bauer, K. A.; Donati, M. B.; Gould, M.; Samama, M.
M.; Weitz, J. I. Parenteral Anticoagulants: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest 2008, 133, 141S−159S.
(128) Turpie, A. G. G. Selective factor Xa inhibition with
fondaparinux: from concept to clinical benefit. Eur. Heart J. Suppl.
2008, 10, C1−C7.
(129) Pinto, D. J. P.; Smallheer, J. M.; Cheney, D. L.; Knabb, R. M.;
Wexler, R. R. Factor Xa inhibitors: Next-generation antithrombotic
agents. J. Med. Chem. 2010, 53, 6243−6274.
(130) Roehrig, S.; Straub, A.; Pohlmann, J.; Lampe, T.; Pernerstorfer,
J.; Schlemmer, K.-H.; Reinemer, P.; Perzborn, E. Discovery of the
novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomor-
pholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxa-
mide (BAY 59-7939): An oral, direct factor Xa inhibitor. J. Med. Chem.
2005, 48, 5900−5908.
(131) Perzborn, E.; Strassburger, J.; Wilmen, A.; Pohlmann, J.;
Roehrig, S.; Schlemmer, K. H.; Straub, A. In vitro and in vivo studies of
the novel antithrombotic agent BAY 59−7939 -an oral, direct factor Xa
inhibitor. J. Thromb. Haemostasis 2005, 3, 514−521.
(132) Kubitza, D.; Becka, M.; Wensing, G.; Voith, B.; Zuehlsdorf, M.
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939–an
oral, direct Factor Xa inhibitor–after multiple dosing in healthy male
subjects. Eur. J. Clin. Pharmacol. 2005, 61, 873−880.
(133) Trujillo, T.; Dobesh, P. P. Clinical use of rivaroxaban:
Pharmacokinetic and pharmacodynamic rationale for dosing regimens
in different indications. Drugs 2014, 74, 1587−1603.
(134) Budovich, A.; Zargarova, O.; Nogid, A. Role of apixaban
(Eliquis) in the treatment and prevention of thromboembolic disease.
Pharm. Ther. 2013, 38, 206−231.
(135) Schaefer, J. K.; McBane, R. D.; Wysokinski, W. E. How to
choose appropriate direct oral anticoagulant for patient with
nonvalvular atrial fibrillation. Ann. Hematol. 2016, 95, 437−449.
(136) Pinto, D. J. P.; Orwat, M. J.; Koch, S.; Rossi, K. A.; Alexander,
R. S.; Smallwood, A.; Wong, P. C.; Rendina, A. R.; Luettgen, J. M.;
Knabb, R. M.; He, K.; Xin, B.; Wexler, R. R.; Lam, P. Y. S. Discovery of
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl]phenyl)-4,5,6,7-
tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban,
BMS-562247), a highly potent, selective, efficacious, and orally
bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem.
2007, 50, 5339−5356.
(137) Furugohri, T.; Isobe, K.; Honda, Y.; Kamisato-Matsumoto, C.;
Sugiyama, N.; Nagahara, T.; Morishima, Y.; Shibano, T. DU-176b, a
potent and orally active factor Xa inhibitor: in vitro and in vivo
pharmacological profiles. J. Thromb. Haemostasis 2008, 6, 1542−1549.
(138) Zhang, P.; Huang, W.; Wang, L.; Bao, L.; Jia, Z. J.; Bauer, S.
M.; Goldman, E. A.; Probst, G. D.; Song, Y.; Su, T.; Fan, J.; Wu, Y.; Li,
W.; Woolfrey, J.; Sinha, U.; Wong, P. W.; Edwards, S. T.; Arfsten, A.
E.; Clizbe, L. A.; Kanter, J.; Pandey, A.; Park, G.; Hutchaleelaha, A.;
Lambing, J. L.; Hollenbach, S. J.; Scarborough, R. M.; Zhu, B.-Y.
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-
(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a
highly potent, selective, and orally efficacious factor Xa inhibitor.
Bioorg. Med. Chem. Lett. 2009, 19, 2179−2185.
(139) Fujimoto, T.; Imaeda, Y.; Konishi, N.; Hiroe, K.; Kawamura,
M.; Textor, G. P.; Aertgeerts, K.; Kubo, K. Discovery of a
tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent,
selective, and orally active factor Xa inhibitor. J. Med. Chem. 2010, 53,
3517−3531.
(140) Hirayama, F.; Koshio, H.; Ishihara, T.; Hachiya, S.; Sugasawa,
K.; Koga, Y.; Seki, N.; Shiraki, R.; Shigenaga, T.; Iwatsuki, Y.; Moritani,
Y.; Mori, K.; Kadokura, T.; Kawasaki, T.; Matsumoto, Y.; Sakamoto,
S . ; Tsukamoto, S . - i . Discovery of N -[2-hydroxy-6-(4-
methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide
(darexaban, YM150) as a potent and orally available factor Xa
inhibitor. J. Med. Chem. 2011, 54, 8051−8065.
(141) Kohrt, J. T.; Bigge, C. F.; Bryant, J. W.; Casimiro-Garcia, A.;
Chi, L.; Cody, W. L.; Dahring, T.; Dudley, D. A.; Filipski, K. J.; Haarer,
S.; Heemstra, R.; Janiczek, N.; Narasimhan, L.; McClanahan, T.;
Peterson, J. T.; Sahasrabudhe, V.; Schaum, R.; Van Huis, C. A.; Welch,
K. M.; Zhang, E.; Leadley, R. J.; Edmunds, J. J. The discovery of
(2R,4R)-N-(4-chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)-
phenyl)-4- methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an
orally efficacious factor Xa inhibitor. Chem. Biol. Drug Des. 2007, 70,
100−112.
(142) Guertin, K. R.; Choi, Y. M. The discovery of the factor Xa
inhibitor otamixaban: from lead identification to clinical development.
Curr. Med. Chem. 2007, 14, 2471−2481.
(143) Pruitt, J. R.; Pinto, D. J.; Galemmo, R. A., Jr.; Alexander, R. S.;
Rossi, K. A.; Wells, B. L.; Drummond, S.; Bostrom, L. L.; Burdick, D.;
Bruckner, R.; Chen, H.; Smallwood, A.; Wong, P. C.; Wright, M. R.;
Bai, S.; Luettgen, J. M.; Knabb, R. M.; Lam, P. Y.; Wexler, R. R.
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-
2′-(aminosulfonyl)[1,1′-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide
(DPC602), a potent, selective, and orally bioavailable factor Xa
inhibitor. J. Med. Chem. 2003, 46, 5298−5315.
(144) Cohen, A. T.; Harrington, R. A.; Goldhaber, S. Z.; Hull, R. D.;
Wiens, B. L.; Gold, A.; Hernandez, A. F.; Gibson, C. M. Extended
thromboprophylaxis with betrixaban in acutely ill medical patients. N.
Engl. J. Med. 2016, 375, 534−544.
(145) Steg, P. G.; Mehta, S. R.; Jukema, J. W.; Lip, G. Y. H.; Gibson,
C. M.; Kovar, F.; Kala, P.; Garcia-Hernandez, A.; Renfurm, R. W.;
Granger, C. B. RUBY-1: a randomized, double-blind, placebo-
controlled trial of the safety and tolerability of the novel oral factor
Xa inhibitor darexaban (YM150) following acute coronary syndrome.
Eur. Heart J. 2011, 32, 2541−2554.
(146) Gomez, K.; Bolton-Maggs, P. Factor XI deficiency.
Haemophilia 2008, 14, 1183−1189.
(147) Renne, T.; Oschatz, C.; Seifert, S.; Muller, F.; Antovic, J.;
Karlman, M.; Benz, P. M. Factor XI deficiency in animal models. J.
Thromb. Haemostasis 2009, 7 (Suppl. 1), 79−83.
(148) Muller, F.; Gailani, D.; Renne, T. Factor XI and XII as
antithrombotic targets. Curr. Opin. Hematol. 2011, 18, 349−355.
(149) Younis, H. S.; Crosby, J.; Huh, J.-I.; Lee, H. S.; Rime, S.;
Monia, B.; Henry, S. P. Antisense inhibition of coagulation factor XI
prolongs APTT without increased bleeding risk in cynomolgus
monkeys. Blood 2012, 119, 2401−2408.
(150) http://pharma.bayer.com/en/innovation-partnering/
development-pipeline/ (accessed October 10, 2017).
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.7b00772
J. Med. Chem. XXXX, XXX, XXX−XXX
U
(151) Buller, H. R.; Bethune, C.; Bhanot, S.; Gailani, D.; Monia, B.
P.; Raskob, G. E.; Segers, A.; Verhamme, P.; Weitz, J. I. Investigators,
F.-A. T. Factor XI antisense oligonucleotide for prevention of venous
thrombosis. N. Engl. J. Med. 2015, 372, 232−240.
(152) Al-Horani, R. A.; Desai, U. R. Factor XIa inhibitors: A review
of the patent literature. Expert Opin. Ther. Pat. 2016, 26, 323−345.
(153) Pinto, D. J. P.; Smallheer, J. M.; Corte, J. R.; Austin, E. J. D.;
Wang, C.; Fang, T.; Smith, L. M.; Rossi, K. A.; Rendina, A. R.; Bozarth,
J. M.; Zhang, G.; Wei, A.; Ramamurthy, V.; Sheriff, S.; Myers, J. E.;
Morin, P. E.; Luettgen, J. M.; Seiffert, D. A.; Quan, M. L.; Wexler, R. R.
Structure-based design of inhibitors of coagulation factor XIa with
novel P1 moieties. Bioorg. Med. Chem. Lett. 2015, 25, 1635−1642.
(154) Corte, J. R.; Fang, T.; Osuna, H.; Pinto, D. J.; Rossi, K. A.;
Myers, J. E., Jr.; Sheriff, S.; Lou, Z.; Zheng, J. J.; Harper, T. W.;
Bozarth, J. M.; Wu, Y.; Luettgen, J. M.; Seiffert, D. A.; Decicco, C. P.;
Wexler, R. R.; Quan, M. L. Structure-based design of macrocyclic
factor XIa inhibitors: Discovery of the macrocyclic amide linker. J.
Med. Chem. 2017, 60, 1060−1075.
(155) Sutton, J. C.; Bolton, S. A.; Hartl, K. S.; Huang, M. H.; Jacobs,
G.; Meng, W.; Ogletree, M. L.; Pi, Z.; Schumacher, W. A.; Seiler, S. M.;
Slusarchyk, W. A.; Treuner, U.; Zahler, R.; Zhao, G.; Bisacchi, G. S.
Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based
tryptase inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 3229−3233.
(156) Wilmouth, R. C.; Kassamally, S.; Westwood, N. J.; Sheppard,
R. J.; Claridge, T. D. W.; Aplin, R. T.; Wright, P. A.; Pritchard, G. J.;
Schofield, C. J. Mechanistic insights into the inhibition of serine
proteases by monocyclic lactams. Biochemistry 1999, 38, 7989−7998.
(157) Deng, H.; Bannister, T. D.; Jin, L.; Babine, R. E.; Quinn, J.;
Nagafuji, P.; Celatka, C. A.; Lin, J.; Lazarova, T. I.; Rynkiewicz, M. J.;
Bibbins, F.; Pandey, P.; Gorga, J.; Meyers, H. V.; Abdel-Meguid, S. S.;
Strickler, J. E. Synthesis, SAR exploration, and X-ray crystal structures
of factor XIa inhibitors containing an α-ketothiazole arginine. Bioorg.
Med. Chem. Lett. 2006, 16, 3049−3054.
(158) Fjellström, O.; Akkaya, S.; Beisel, H.-G.; Eriksson, P.-O.;
Erixon, K.; Gustafsson, D.; Jurva, U.; Kang, D.; Karis, D.; Knecht, W.;
Nerme, V.; Nilsson, I.; Olsson, T.; Redzic, A.; Roth, R.; Sandmark, J.;
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